Advanced

Involvement of the serotonin system in L-dopa-induced dyskinesias

Carta, Manolo LU ; Carlsson, Thomas LU ; Muñoz, Ana LU ; Kirik, Deniz LU and Björklund, Anders LU (2008) In Parkinsonism and Related Disorders 14 (Suppl 2). p.8-154
Abstract

The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over time, and side-effects, such as dyskinesias, appear--limiting the use of the drug in the advanced stage of the disease. Serotonergic neurons are able to convert L-dopa to dopamine and to store this neurotransmitter in synaptic vesicles. This peculiarity might be very important in the advanced disease, when most of the dopaminergic neurons have degenerated. Indeed, an increasing body of evidence points to dopamine released as a false neurotransmitter from the serotonin terminals as the main pre-synaptic determinant of L-dopa-induced dyskinesias in animal models of Parkinson's disease. These findings make the serotonin system an intriguing... (More)

The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over time, and side-effects, such as dyskinesias, appear--limiting the use of the drug in the advanced stage of the disease. Serotonergic neurons are able to convert L-dopa to dopamine and to store this neurotransmitter in synaptic vesicles. This peculiarity might be very important in the advanced disease, when most of the dopaminergic neurons have degenerated. Indeed, an increasing body of evidence points to dopamine released as a false neurotransmitter from the serotonin terminals as the main pre-synaptic determinant of L-dopa-induced dyskinesias in animal models of Parkinson's disease. These findings make the serotonin system an intriguing target for anti-dyskinetic therapies.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Animals, Dopamine Agents, Dyskinesia, Drug-Induced, Humans, Levodopa, Serotonin, Journal Article, Research Support, Non-U.S. Gov't, Review
in
Parkinsonism and Related Disorders
volume
14
issue
Suppl 2
pages
8 - 154
publisher
Elsevier
external identifiers
  • scopus:47049130578
ISSN
1353-8020
DOI
10.1016/j.parkreldis.2008.04.021
language
English
LU publication?
yes
id
3201f509-3655-47d3-bfc7-385284a6113f
date added to LUP
2016-11-23 14:16:11
date last changed
2017-10-01 05:26:20
@article{3201f509-3655-47d3-bfc7-385284a6113f,
  abstract     = {<p>The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over time, and side-effects, such as dyskinesias, appear--limiting the use of the drug in the advanced stage of the disease. Serotonergic neurons are able to convert L-dopa to dopamine and to store this neurotransmitter in synaptic vesicles. This peculiarity might be very important in the advanced disease, when most of the dopaminergic neurons have degenerated. Indeed, an increasing body of evidence points to dopamine released as a false neurotransmitter from the serotonin terminals as the main pre-synaptic determinant of L-dopa-induced dyskinesias in animal models of Parkinson's disease. These findings make the serotonin system an intriguing target for anti-dyskinetic therapies.</p>},
  author       = {Carta, Manolo and Carlsson, Thomas and Muñoz, Ana and Kirik, Deniz and Björklund, Anders},
  issn         = {1353-8020},
  keyword      = {Animals,Dopamine Agents,Dyskinesia, Drug-Induced,Humans,Levodopa,Serotonin,Journal Article,Research Support, Non-U.S. Gov't,Review},
  language     = {eng},
  number       = {Suppl 2},
  pages        = {8--154},
  publisher    = {Elsevier},
  series       = {Parkinsonism and Related Disorders},
  title        = {Involvement of the serotonin system in L-dopa-induced dyskinesias},
  url          = {http://dx.doi.org/10.1016/j.parkreldis.2008.04.021},
  volume       = {14 },
  year         = {2008},
}